Selection of GalNAc-conjugated siRNAs with limited off-Target-driven rat hepatotoxicity

Nature Communications

Volumn 9, Issue 1, 2018, Pages

  Janas, Maja M ^a   Schlegel, Mark K ^a   Harbison, Carole E ^a   Yilmaz, Vedat O ^a   Jiang, Yongfeng ^a   Parmar, Rubina ^a   Zlatev, Ivan ^a   Castoreno, Adam ^a   Xu, Huilei ^a   Shulga Morskaya, Svetlana ^a   Rajeev, Kallanthottathil G ^a   Manoharan, Muthiah ^a   Keirstead, Natalie D ^a   Maier, Martin A ^a   Jadhav, Vasant ^a  

^a ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ARGONAUTE 2 PROTEIN; MESSENGER RNA; N ACETYLGALACTOSAMINE; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA;

BIOACCUMULATION; DOSE-RESPONSE RELATIONSHIP; LIGAND; METABOLITE; ORGANIC COMPOUND; PHYSIOLOGY; RNA; RODENT; TOXICITY;

3' UNTRANSLATED REGION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONJUGATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE KNOCKDOWN; GENETIC ASSOCIATION; GENETIC TRANSFECTION; LIVER CELL; LIVER TISSUE; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; RAT; RNA HYBRIDIZATION; RNA INTERFERENCE; UPREGULATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; GENETICS; LIVER; METABOLISM; SPRAGUE DAWLEY RAT;

RATTUS; RODENTIA;

ACETYLGALACTOSAMINE; ANIMALS; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 85042225440     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-018-02989-4     Document Type: Article

References (43)

1. Carthew, R. W. & Sontheimer, E. J. Origins and mechanisms of miRNAs and siRNAs. Cell 136, 642-655 (2009).
2. Nakanishi, K. Anatomy of RISC: how do small RNAs and chaperones activate Argonaute proteins? Wiley Interdiscip. Rev. RNA 7, 637-660 (2016).
3. Swarts, D. C. et al. The evolutionary journey of Argonaute proteins. Nat. Struct. Mol. Biol. 21, 743-753 (2014).
4. Liu, J. et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 1437-1441 (2004).
5. Wittrup, A. & Lieberman, J. Knocking down disease: A progress report on siRNA therapeutics. Nat. Rev. Genet. 16, 543-552 (2015).
6. Matsuda, S. et al. siRNA conjugates carrying sequentially assembled trivalent N-Acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem. Biol. 10, 1181-1187 (2015).
7. Rajeev, K. G. et al. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-Acetylgalactosamine elicits robust gene silencing in vivo. Chembiochem 16, 903-908 (2015).
8. Nair, J. K. et al. Multivalent N-Acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958-16961 (2014).
9. Manoharan, M. RNA interference and chemically modified small interfering RNAs. Curr. Opin. Chem. Biol. 8, 570-579 (2004).
10. Bumcrot, D., Manoharan, M., Koteliansky, V. & Sah, D. W. RNAi therapeutics: A potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2, 711-719 (2006).
11. Foster, D. J., et al. Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates. Mol. Ther. https://doi.org/10.1016/j.ymthe.2017.12.021 (2018).
12. Janas, M. M. et al. Impact of oligonucleotide structure, chemistry, and delivery method on in vitro cytotoxicity. Nucleic Acids Ther. 27, 11-22 (2016).
13. Janas, M. M. et al. Exposure to siRNA-GalNAc conjugates in systems of the standard test battery for genotoxicity. Nucleic Acids Ther. 26, 363-371 (2016).
14. Liang, X. H., Sun, H., Shen, W. & Crooke, S. T. Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Res. 43, 2927-2945 (2015).
15. Shen, W., Liang, X. H., Sun, H. & Crooke, S. T. 2'-fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF. Nucleic Acids Res. 43, 4569-4578 (2015).
16. Crooke, S. T., Wang, S., Vickers, T. A., Shen, W. & Liang, X. H. Cellular uptake and trafficking of antisense oligonucleotides. Nat. Biotechnol. 35, 230-237 (2017).
17. Frazier, K. S. Antisense oligonucleotide therapies: The promise and the challenges from a toxicologic pathologist's perspective. Toxicol. Pathol. 43, 78-89 (2015).
18. Valdmanis, P. N. et al. RNA interference-induced hepatotoxicity results from loss of the first synthesized isoform of microRNA-122 in mice. Nat. Med. 22, 557-562 (2016).
19. Grimm, D. et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541 (2006).
20. Jackson, A. L. et al. Expression profiling reveals off-Target gene regulation by RNAi. Nat. Biotechnol. 21, 635-637 (2003).
21. Jackson, A. L. et al. Widespread siRNA "off-Target" transcript silencing mediated by seed region sequence complementarity. RNA 12, 1179-1187 (2006).
22. Birmingham, A. et al. 3' UTR seed matches, but not overall identity, are associated with RNAi off-Targets. Nat. Methods 3, 199-204 (2006).
23. Burel, S. A. et al. Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. Nucleic Acids Res. 44, 2093-2109 (2016).
24. Kamola, P. J. et al. In silico and in vitro evaluation of exonic and intronic off-Target effects form a critical element of therapeutic ASO gapmer optimization. Nucleic Acids Res. 43, 8638-8650 (2015).
25. Wilczynska, A. & Bushell, M. The complexity of miRNA-mediated repression. Cell Death Differ. 22, 22-33 (2015).
26. Zlatev, I. et al. REVERSIR™ platform for the tailored control of GalNAc-siRNA conjugate pharmacology. Nat. Biotechnol. in press (2018).
27. John, M. et al. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 449, 745-747 (2007).
28. Schirle, N. T. & MacRae, I. J. The crystal structure of human Argonaute2. Science 336, 1037-1040 (2012).
29. Wang, Y. et al. Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes. Nature 461, 754-761 (2009).
30. Parmar, R. et al. 5'-(E)-vinylphosphonate: A stable phosphate mimic can improve the RNAi activity of siRNA-GalNAc conjugates. Chembiochem 17, 985-989 (2016).
31. Weitzer, S. & Martinez, J. The human RNA kinase hClp1 is active on 3' transfer RNA exons and short interfering RNAs. Nature 447, 222-226 (2007).
32. Haringsma, H. J. et al. mRNA knockdown by single strand RNA is improved by chemical modifications. Nucleic Acids Res. 40, 4125-4136 (2012).
33. Jadhav, V. et al. Modulation of the pharmacology activity of conjugated siRNA by REVERSIR compounds. Alnylam Pharmaceuticals patent WO2016100716A1. (2016).
34. Schlegel, M. K. et al. Chirality dependent potency enhancement and structural impact of glycol nucleic acid modification on siRNA. J. Am. Chem. Soc. 139, 8537-8546 (2017).
35. Bramsen, J. B. et al. A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-Target effects. Nucleic Acids Res. 38, 5761-5773 (2010).
36. Mook, O. et al. In vivo efficacy and off-Target effects of locked nucleic acid (LNA) and unlocked nucleic acid (UNA) modified siRNA and small internally segmented interfering RNA (sisiRNA) in mice bearing human tumor xenografts. Artif. DNA PNA XNA 1, 36-44 (2010).
37. Vaish, N. et al. Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res. 39, 1823-1832 (2011).
38. Lee, H. S. et al. Abasic pivot substitution harnesses target specificity of RNA interference. Nat. Commun. 6, 10154 (2015).
39. Seok, H., Jang, E. S. & Chi, S. W. Rationally designed siRNAs without miRNA-like off-Target repression. BMB Rep. 49, 135-136 (2016).
40. Elkayam, E. et al. siRNA carrying an (E)-vinylphosphonate moiety at the 5' end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2. Nucleic Acids Res. 45, 3528-3536 (2016).
41. Liao, Y., Smyth, G. K. & Shi, W. featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923-930 (2014).
42. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
43. Edgar, R., Domrachev, M. & Lash, A. E. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30, 207-210 (2002).